Current Report Filing (8-k)
April 15 2022 - 05:15PM
Edgar (US Regulatory)
false 0001318641 0001318641 2022-04-11
2022-04-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): April 11,
2022
Statera Biopharma, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
|
001-32954
|
20-0077155
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
|
|
|
|
2537 Research Boulevard, Suite 201
Fort Collins, CO 80526
|
|
(Address of Principal Executive Offices and zip code)
|
|
|
|
|
(888) 613-8802
|
|
(Registrant's Telephone Number, Including Area Code)
|
Securities registered or to be registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.005
|
STAB
|
NASDAQ Capital Market
|
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item
4.01
Changes in Registrant’s Certifying Accountant.
On April 11, 2022, Tuner, Stone & Company, LLP (“TSC”) advised
the Audit Committee of the Board of Directors (the “Audit
Committee”) of Statera Biopharma, Inc., a Delaware corporation (the
“Company”) of TSC’s resignation as the Company’s independent
registered public accounting firm, effective on that date. The
Audit Committee did not request, recommend or approve the
resignation of TSC. In its letter of resignation, TSC
indicated that based on information that had come to its attention,
TSC was resigning and would no longer be able to provide auditing
services. The resignation was not the result of a disagreement
between the Company and the TSC on accounting principles or
practices, financial statement disclosure, or auditing scope or
procedure during the two most recently completed fiscal
years.
The Company has begun a search process to identify a new
independent registered public accounting firm. The Company will
disclose its engagement of a new independent registered public
accounting firm in accordance with SEC rules and regulations once
the process has been completed.
ITEM 9.01
FINANCIAL
STATEMENTS AND EXHIBITS.
(d) Exhibits
Exhibit
No
Description
104
Cover Page Interactive Data File (embedded within the Inline XBRL
document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
Statera Biopharma,
Inc.
|
|
|
|
|
|
|
|
|
|
Date:
April 15, 2022
|
By:
|
/s/ Michael
K. Handley
|
|
|
Name:
|
Michael K.
Handley
|
|
|
Title:
|
Chief Executive
Officer
|
|
Statera BioPharma (NASDAQ:STAB)
Historical Stock Chart
From Jan 2023 to Feb 2023
Statera BioPharma (NASDAQ:STAB)
Historical Stock Chart
From Feb 2022 to Feb 2023